ASCO Highlights

flipper_slider

Editor's Choice

Prof. Martin Reck explains the latest data from the CheckMate 017 and 057 trials of nivolumab in NSCLC. He also discusses new strategies for immunotherapy is NSCLC. FILMED AT THE AMERICAN SOCIETY OF CLINICAL...

ASCO Highlights Videos

Part 3 of 3 - Dr Domenica Lorusso tells us which presentations, in gynecological cancer, she has found particularly interesting at ASCO 2017. Speaker disclosures: Advisory Board for Clovis Oncology, Astra Zeneca, PharmaMar, Roche. Filmed at the American Society of Clinical Oncology (ASCO)...
Part 2 of 3 – Dr Domenica Lorusso discusses the ICON 6 trial and the difficulties in analyzing survival benefits in ovarian cancer patients. She also discusses the ANTHALYA study and toxicity of bevacizumab. Speaker disclosures: Advisory Board for Clovis Oncology, Astra Zeneca, PharmaMar, Roche...
Part 1 of 3 – Dr Domenica Lorusso discusses the results of the phase III LION study and the DESKTOP III trial in ovarian cancer. Speaker disclosures: Advisory Board for Clovis Oncology, Astra Zeneca, PharmaMar, Roche. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting,...
Jeff Evans discusses the key findings from the phase III REFLECT study, and how these results might impact the future management of liver cancer patients. Speaker disclosures: Consultancy for Eisai for Advisory Boards. Support for clinical trials (all payments to university). Filmed at the...
Part 2 of 2 – Dr Marc Peeters, from our European Editorial Board, explains the move from treating patients with BRAF-targeting drugs, to using combination therapy to target the EGFR pathway in BRAF-mutant mCRC. He also discusses the BEACON CRC study, which uses this combination of binimetinib,...
Part 1 of 2 – Dr Marc Peeters, from our European Editorial Board, summarizes the clinical use of circulating tumor DNA in colorectal cancer (CRC). He also discusses the difficulties of making interstudy comparisons between the outcomes of second-line trials in metastatic CRC. Speaker disclosures...
Part 2 of 2 - Dr Maurice Pérol talks to us about the recent IFCT-GFPC 0502-Eco phase III study in optimization of maintenance therapy in non-small cell lung cancer, by tailoring the treatment according to the response from induction chemotherapy. Filmed at the American Society of Clinical...
Part 1 of 2 – Dr Maurice Pérol discusses the use of programmed death-ligand 1 (PD-L1) as a predictive biomarker in non-small cell lung cancer. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, US, June 2017
Prof. Christian Rolfo describes the importance of molecular profiling in cancer patients, and the addition of liquid biopsy. Support: The filming of this video was supported by Prometheus. FILMED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, JUNE 2016 CAN YOU DESCRIBE...
Prof. Martin Reck explains the latest data from the CheckMate 017 and 057 trials of nivolumab in NSCLC. He also discusses new strategies for immunotherapy is NSCLC. FILMED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, JUNE 2016 CAN YOU TELL US ABOUT THE LATEST DATA FROM...
Dr. Howard Kaufman discusses the key findings of the PROCLAIM Registry and IL-2. FILMED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, JUNE 2016 COULD YOU GIVE US AN OVERVIEW OF THE RATIONALE BEHIND THE PROCLAIM REGISTRY? 00:10 – The Proclaim Registry was really designed...
Dr. Ajjai Alva discusses IL-2 and the current treatment landscape for renal cell carcinoma and metastatic melanoma. Disclosure: Dr Alva served on an Advisory Board with Prometheus in 2015. Support: The filming of this video was supported by Prometheus. FILMED AT THE AMERICAN SOCIETY OF...
Dr. Nicola Fazio explains the findings of the RADIANT-4 Trial and discusses mTOR inhibition in neuroendocrine tumors. FILMED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, JUNE 2016 CAN YOU TELL US ABOUT THE FINDINGS OF THE RADIANT-4 TRIAL? 00:09 – The RADIANT-4 trial was...
Patrick Schoffski and Prof. John Crown discuss eribulin in breast cancer and advanced liposarcoma. This covers data presented at ASCO 2016 and the importance of the overall survival benefit demonstrated in these two tumours. FILMED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING...